Education
About Us
Working with TipRanks
Follow Us
Immunoprecise Antibodies Ltd. (IPA)
:IPA
IPA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.27 - $2.41
Previous CloseN/A
Volume74.57K
Average Volume (3M)1.81M
Market Cap
$75.69M
Enterprise Value$22.20M
Total Cash (Recent Filing)$12.91M
Total Debt (Recent Filing)$12.93M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Sep 11, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding46,154,118
10 Day Avg. Volume1,724,587
30 Day Avg. Volume1,814,244
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.29
Enterprise Value/Revenue0.92
Enterprise Value/Gross Profit1.82
Enterprise Value/Ebitda-0.74
Forecast
1Y Price Target
$4.00Price Target Upside143.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
AI Business GrowthAI business contribution is set to grow with BioStrand increasing its revenue share significantly, enhancing overall financial performance.
Financial PerformanceImmunoPrecise Antibodies reported positive financial results with revenues of CDN$7.0 million, up 8% year-over-year, and a reduced net loss compared to the previous year.
Research And DevelopmentThe LENSai platform's recent breakthroughs, including strategic partnerships and advancements in antibody development, highlight significant R&D progress.
Bears Say
Market UncertaintiesIPA shares have experienced a decline due to overall market dips and uncertainties related to potential drug tariffs and government R&D spending.
Operational ChallengesThe impact of the EU facility divestiture has been partially offset by growth in Canadian operations but remains a challenge.
ImmunoPrecise Antibodies News
IPA FAQ
What was Immunoprecise Antibodies Ltd.’s price range in the past 12 months?
Immunoprecise Antibodies Ltd. lowest stock price was $0.27 and its highest was $2.41 in the past 12 months.
What is Immunoprecise Antibodies Ltd.’s market cap?
Immunoprecise Antibodies Ltd.’s market cap is $75.69M.
When is Immunoprecise Antibodies Ltd.’s upcoming earnings report date?
Immunoprecise Antibodies Ltd.’s upcoming earnings report date is Sep 11, 2025 which is in 37 days.
How were Immunoprecise Antibodies Ltd.’s earnings last quarter?
Immunoprecise Antibodies Ltd. released its earnings results on Jul 29, 2025. The company reported -$0.036 earnings per share for the quarter, the consensus estimate of -$0.036 by $0.
Is Immunoprecise Antibodies Ltd. overvalued?
According to Wall Street analysts Immunoprecise Antibodies Ltd.’s price is currently Undervalued.
Does Immunoprecise Antibodies Ltd. pay dividends?
Immunoprecise Antibodies Ltd. does not currently pay dividends.
What is Immunoprecise Antibodies Ltd.’s EPS estimate?
Immunoprecise Antibodies Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immunoprecise Antibodies Ltd. have?
Immunoprecise Antibodies Ltd. has 46,154,118 shares outstanding.
What happened to Immunoprecise Antibodies Ltd.’s price movement after its last earnings report?
Immunoprecise Antibodies Ltd. reported an EPS of -$0.036 in its last earnings report, expectations of -$0.036. Following the earnings report the stock price went down -14.851%.
Which hedge fund is a major shareholder of Immunoprecise Antibodies Ltd.?
Currently, no hedge funds are holding shares in IPA
ImmunoPrecise Antibodies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (143.90% Upside)
$4.00 (143.90% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 34.4%
Last 30 Days ▲ 34.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
112.79%
12-Months-Change
Fundamentals
Return on Equity
-102.69%
Trailing 12-Months
Asset Growth
-26.32%
Trailing 12-Months
Company Description
Immunoprecise Antibodies Ltd.
ImmunoPrecise Antibodies (IPA) is a biotechnology company that operates in the life sciences sector, specializing in the discovery and development of therapeutic antibodies. The company provides a full suite of services covering the entire antibody discovery process, utilizing advanced technologies such as hybridoma, B-cell selection, and phage display. IPA caters to pharmaceutical and biotechnology companies, as well as academic and research institutions, offering tailored solutions to accelerate drug discovery and development.
IPA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including record-setting revenue, improved gross margins, and strong growth in key segments. Despite slight delays in the divestiture process and marginal annual revenue growth, the overall financial and strategic progress positions the company well for future success.Read More>IPA Stock 12 Month Forecast
Average Price Target
$4.00
▲(143.90%Upside)
Technical Analysis
Ownership Overview
5.23% Insiders
0.02% Mutual Funds
0.12% Other Institutional Investors
94.63% Public Companies and
Individual Investors